Toll Free: 1-888-928-9744

2017-2022 Global and Japan Live Attenuated Vaccine Market Analysis Report

Published: Aug 9, 2017 | Pages: 109 | Publisher: JP Research | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

The global Live Attenuated Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Live Attenuated Vaccine market's development status and future trend in the global and Japan. It splits Live Attenuated Vaccine market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include
    Astellas Pharma (Japan)
    CSL Limited (Australia)
    Emergent BioSolutions (U.S.)
    GlaxoSmithKline (U.K.)
    Johnson & Johnson (U.S.)
    MedImmune (U.S.)
    Merck & Co (U.S.)
    Pfizer (U.S.)
    Sanofi Pasteur (France)
    Serum Institute of India Pvt (India)

Geographically, this report splits the Global market into the following regions:
    Asia Pacific
        Japan
            Tokyo
            Yokohama
            Osaka
            Nagoya
            Others
        China
        Korea
        India
        Others
    Europe
        France
        Germany
        United Kingdom
        Italy
        Russia
        Others
    North America
        United States
        Canada
    Latin America
        Brazil
        Mexico
        Others
    Southeast Asia
        Singapore
        Malaysia
        Vietnam
        Myanmar
        Thailand
        Indonesia
        Philippines
        Others
    Middle East & Africa
        Saudi Arabia
        Iran
        UAE
        Turkey
        Israel
        Egypt
        South Africa
        Others

On the basis of product, the Live Attenuated Vaccine market is primarily split into
By End User
    Pediatrics
    Adults
By Disease Indication
    Pneumococcal
    Influenza
    HPV
    Hepatitis
    Rotavirus

Key Applications
    Hospital
    Medical Center
    Others


 Table of Contents

2017-2022 Global and Japan Live Attenuated Vaccine Market Analysis Report
1 Live Attenuated Vaccine Overview
    1.1 Product Overview and Scope of Live Attenuated Vaccine
    1.2 Global and Japan Live Attenuated Vaccine Market by Applications/End Users
        1.2.1 Japan Live Attenuated Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
            1.2.1.1 Japan Live Attenuated Vaccine Sales (K Pcs) and Market Share by Applications (2012-2017)
            1.2.1.2 Japan Live Attenuated Vaccine Sales Growth Rate (%) by Applications (2012-2017)
            1.2.1.3 Market Drivers and Opportunities
        1.2.2 Japan Live Attenuated Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
        1.2.3 Global Live Attenuated Vaccine Sales by Application (2012-2017)
            1.2.3.1 Global Live Attenuated Vaccine Sales (K Pcs) and Market Share by Applications (2012-2017)
            1.2.3.2 Global Live Attenuated Vaccine Sales Growth Rate (%) by Applications (2012-2017)
            1.2.3.3 Market Drivers and Opportunities
        1.2.4 Global Live Attenuated Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
        1.2.5 Hospital
        1.2.6 Medical Center
        1.2.7 Others
    1.3 Global and Japan Market Size (Sales and Revenue) of Live Attenuated Vaccine (2012-2017)
        1.3.1 Japan Market Size (Sales and Revenue) of Live Attenuated Vaccine (2012-2017)
            1.3.1.1 Japan Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (%) (2012-2017)
            1.3.1.2 Japan Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
        1.3.2 Global Market Size (Sales and Revenue) of Live Attenuated Vaccine (2012-2017)
            1.3.2.1 Global Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (%) (2012-2017)
            1.3.2.2 Global Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
    1.4 Global and Japan Classification of Live Attenuated Vaccine by End User
        1.4.1 Japan Live Attenuated Vaccine Sales (K Pcs) and Market Share by End User (2012-2017)
        1.4.2 Global Live Attenuated Vaccine Sales (K Pcs) and Market Share by End User (2012-2017)
        1.4.3 Japan Live Attenuated Vaccine Revenue (Million USD) and Market Share by End User (2012-2017)
        1.4.4 Global Live Attenuated Vaccine Revenue (Million USD) and Market Share by End User (2012-2017)
        1.4.5 Japan Live Attenuated Vaccine Price (USD/Pcs) by End User (2012-2017)
        1.4.6 Global Live Attenuated Vaccine Price (USD/Pcs) by End User (2012-2017)
        1.4.7 Japan Live Attenuated Vaccine Sales Growth Rate (%) by End User (2012-2017)
        1.4.8 Global Live Attenuated Vaccine Sales Growth Rate (%) by End User (2012-2017)
        1.4.9 Pediatrics
        1.4.10 Adults
    1.5 Global and Japan Classification of Live Attenuated Vaccine by Disease Indication
        1.5.1 Japan Live Attenuated Vaccine Sales (K Pcs) and Market Share by Disease Indication (2012-2017)
        1.5.2 Global Live Attenuated Vaccine Sales (K Pcs) and Market Share by Disease Indication (2012-2017)
        1.5.3 Japan Live Attenuated Vaccine Revenue (Million USD) and Market Share by Disease Indication (2012-2017)
        1.5.4 Global Live Attenuated Vaccine Revenue (Million USD) and Market Share by Disease Indication (2012-2017)
        1.5.5 Japan Live Attenuated Vaccine Price (USD/Pcs) by Disease Indication (2012-2017)
        1.5.6 Global Live Attenuated Vaccine Price (USD/Pcs) by Disease Indication (2012-2017)
        1.5.7 Japan Live Attenuated Vaccine Sales Growth Rate (%) by Disease Indication (2012-2017)
        1.5.8 Global Live Attenuated Vaccine Sales Growth Rate (%) by Disease Indication (2012-2017)
        1.5.9 Pneumococcal
        1.5.10 Influenza
        1.5.11 HPV
        1.5.12 Hepatitis
        1.5.13 Rotavirus

2 Global and Japan Live Attenuated Vaccine Market Competition by Players/Manufacturers
    2.1 Japan Live Attenuated Vaccine Market Competition by Players/Manufacturers
    2.1.1 Japan Live Attenuated Vaccine Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.1.2 Japan Live Attenuated Vaccine Revenue and Share by Players/Manufacturers (2012-2017)
    2.1.3 Japan Live Attenuated Vaccine Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.1.4 Japan Live Attenuated Vaccine Market Competitive Situation and Trends
        2.1.4.1 Japan Live Attenuated Vaccine Market Concentration Rate
        2.1.4.2 Japan Live Attenuated Vaccine Market Share of Top 3 and Top 5 Players/Manufacturers
        2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
    2.1.5 Japan Players/Manufacturers Live Attenuated Vaccine Manufacturing Base Distribution, Sales Area, Product Types
    2.2 Global Live Attenuated Vaccine Market Competition by Players/Manufacturers
    2.2.1 Global Live Attenuated Vaccine Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2.2 Global Live Attenuated Vaccine Revenue and Share by Players/Manufacturers (2012-2017)
    2.2.3 Global Live Attenuated Vaccine Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.2.4 Global Live Attenuated Vaccine Market Competitive Situation and Trends
        2.2.4.1 Global Live Attenuated Vaccine Market Concentration Rate
        2.2.4.2 Global Live Attenuated Vaccine Market Share of Top 3 and Top 5 Players/Manufacturers
        2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
    2.2.5 Global Players/Manufacturers Live Attenuated Vaccine Manufacturing Base Distribution, Sales Area, Product Types

3 Global and Japan Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
    3.1 Asia Pacific Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
        3.1.1 Japan Live Attenuated Vaccine Sales and Revenue  (2012-2017)
            3.1.1.1 Japan Live Attenuated Vaccine Sales (K Pcs) and Market Share  (2012-2017)
            3.1.1.2 Japan Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.1.1.3 Japan Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.1.2 China Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.1.2.1 China Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.1.2.2 China Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.1.2.3 China Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.1.3 Korea Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.1.3.1 Korea Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.1.3.2 Korea Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.1.3.3 Korea Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.1.4 India Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.1.4.1 India Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.1.4.2 India Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.1.4.3 India Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.1.5 Others Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.1.5.1 Others Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.1.5.2 Others Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.1.5.3 Others Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
    3.2 Europe Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
        3.2.1 France Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.2.1.1 France Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.2.1.2 France Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.2.1.3 France Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.2.2 Germany Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.2.2.1 Germany Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.2.2.2 Germany Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.2.2.3 Germany Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.2.3 United Kingdom Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.2.3.1 United Kingdom Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.2.3.2 United Kingdom Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.2.3.3 United Kingdom Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.2.4 Italy Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.2.4.1 Italy Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.2.4.2 Italy Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.2.4.3 Italy Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.2.5 Russia Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.2.5.1 Russia Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.2.5.2 Russia Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.2.5.3 Russia Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.2.6 Others Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.2.6.1 Others Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.2.6.2 Others Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.2.6.3 Others Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
    3.3 North America Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
        3.3.1 United States Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.3.1.1 United States Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.3.1.2 United States Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.3.1.3 United States Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.3.2 Canada Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.3.2.1 Canada Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.3.2.2 Canada Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.3.2.3 Canada Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
    3.4 Latin America Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
        3.4.1 Brazil Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.4.1.1 Brazil Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.4.1.2 Brazil Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.4.1.3 Brazil Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.4.2 Mexico Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.4.2.1 Mexico Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.4.2.2 Mexico Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.4.2.3 Mexico Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.4.3 Others Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.4.3.1 Others Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.4.3.2 Others Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.4.3.3 Others Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
    3.5 Southeast Asia Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
        3.5.1 Singapore Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.1.1 Singapore Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.1.2 Singapore Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.1.3 Singapore Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.2 Malaysia Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.2.1 Malaysia Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.2.2 Malaysia Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.2.3 Malaysia Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.3 Vietnam Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.3.1 Vietnam Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.3.2 Vietnam Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.3.3 Vietnam Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.4 Myanmar Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.4.1 Myanmar Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.4.2 Myanmar Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.4.3 Myanmar Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.5 Thailand Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.5.1 Thailand Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.5.2 Thailand Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.5.3 Thailand Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.6 Indonesia Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.6.1 Indonesia Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.6.2 Indonesia Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.6.3 Indonesia Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.7 Philippines Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.7.1 Philippines Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.7.2 Philippines Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.7.3 Philippines Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.5.8 Others Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.5.8.1 Others Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.5.8.2 Others Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.5.8.3 Others Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
    3.6 Middle East & Africa Live Attenuated Vaccine Sales and Revenue by Regions (2012-2017)
        3.6.1 Saudi Arabia Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.1.1 Saudi Arabia Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.1.2 Saudi Arabia Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.1.3 Saudi Arabia Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.2 Iran Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.2.1 Iran Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.2.2 Iran Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.2.3 Iran Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.3 UAE Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.3.1 UAE Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.3.2 UAE Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.3.3 UAE Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.4 Turkey Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.4.1 Turkey Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.4.2 Turkey Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.4.3 Turkey Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.5 Israel Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.5.1 Israel Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.5.2 Israel Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.5.3 Israel Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.6 Egypt Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.6.1 Egypt Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.6.2 Egypt Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.6.3 Egypt Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.7 South Africa Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.7.1 South Africa Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.7.2 South Africa Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.7.3 South Africa Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)
        3.6.8 Others Live Attenuated Vaccine Sales and Revenue (2012-2017)
            3.6.8.1 Others Live Attenuated Vaccine Sales (K Pcs) and Market Share (2012-2017)
            3.6.8.2 Others Live Attenuated Vaccine Revenue (Million USD) and Market Share (2012-2017)
            3.6.8.3 Others Live Attenuated Vaccine Price (USD/Pcs)(2012-2017)

4 Global and Japan Live Attenuated Vaccine Players/Manufacturers Profiles and Sales Data
    4.1 Astellas Pharma (Japan)
        4.1.1 Company Basic Information, Manufacturing Base and Competitors
        4.1.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.1.2.1 Product A
            4.1.2.2 Product B
        4.1.3 Astellas Pharma (Japan) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.1.4 Main Business/Business Overview
    4.2 CSL Limited (Australia)
        4.2.1 Company Basic Information, Manufacturing Base and Competitors
        4.2.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.2.2.1 Product A
            4.2.2.2 Product B
        4.2.3 CSL Limited (Australia) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.2.4 Main Business/Business Overview
    4.3 Emergent BioSolutions (U.S.)
        4.3.1 Company Basic Information, Manufacturing Base and Competitors
        4.3.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.3.2.1 Product A
            4.3.2.2 Product B
        4.3.3 Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.3.4 Main Business/Business Overview
    4.4 GlaxoSmithKline (U.K.)
        4.4.1 Company Basic Information, Manufacturing Base and Competitors
        4.4.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.4.2.1 Product A
            4.4.2.2 Product B
        4.4.3 GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.4.4 Main Business/Business Overview
    4.5 Johnson & Johnson (U.S.)
        4.5.1 Company Basic Information, Manufacturing Base and Competitors
        4.5.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.5.2.1 Product A
            4.5.2.2 Product B
        4.5.3 Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.5.4 Main Business/Business Overview
    4.6 MedImmune (U.S.)
        4.6.1 Company Basic Information, Manufacturing Base and Competitors
        4.6.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.6.2.1 Product A
            4.6.2.2 Product B
        4.6.3 MedImmune (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.6.4 Main Business/Business Overview
    4.7 Merck & Co (U.S.)
        4.7.1 Company Basic Information, Manufacturing Base and Competitors
        4.7.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.7.2.1 Product A
            4.7.2.2 Product B
        4.7.3 Merck & Co (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.7.4 Main Business/Business Overview
    4.8 Pfizer (U.S.)
        4.8.1 Company Basic Information, Manufacturing Base and Competitors
        4.8.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.8.2.1 Product A
            4.8.2.2 Product B
        4.8.3 Pfizer (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.8.4 Main Business/Business Overview
    4.9 Sanofi Pasteur (France)
        4.9.1 Company Basic Information, Manufacturing Base and Competitors
        4.9.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.9.2.1 Product A
            4.9.2.2 Product B
        4.9.3 Sanofi Pasteur (France) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.9.4 Main Business/Business Overview
    4.10 Serum Institute of India Pvt (India)
        4.10.1 Company Basic Information, Manufacturing Base and Competitors
        4.10.2 Live Attenuated Vaccine Product Category, Application and Specification
            4.10.2.1 Product A
            4.10.2.2 Product B
        4.10.3 Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.10.4 Main Business/Business Overview

5 Live Attenuated Vaccine Manufacturing Cost Analysis
    5.1 Live Attenuated Vaccine Key Raw Materials Analysis
        5.1.1 Key Raw Materials
        5.1.2 Price Trend of Key Raw Materials
        5.1.3 Key Suppliers of Raw Materials
        5.1.4 Market Concentration Rate of Raw Materials
    5.2 Proportion of Manufacturing Cost Structure
        5.2.1 Raw Materials
        5.2.2 Labor Cost
        5.2.3 Manufacturing Expenses
    5.3 Manufacturing Process Analysis of Live Attenuated Vaccine

6 Industrial Chain, Sourcing Strategy and Downstream Buyers
    6.1 Live Attenuated Vaccine Industrial Chain Analysis
    6.2 Upstream Raw Materials Sourcing
    6.3 Raw Materials Sources of Live Attenuated Vaccine Major Players/Manufacturers in 2016
    6.4 Downstream Buyers

7 Marketing Strategy Analysis, Distributors/Traders
    7.1 Marketing Channel
        7.1.1 Direct Marketing
        7.1.2 Indirect Marketing
        7.1.3 Marketing Channel Development Trend
    7.2 Market Positioning
        7.2.1 Pricing Strategy
        7.2.2 Brand Strategy
        7.2.3 Target Client
    7.3 Distributors/Traders List

8 Market Effect Factors Analysis
    8.1 Technology Progress/Risk
        8.1.1 Substitutes Threat
        8.1.2 Technology Progress in Related Industry
    8.2 Consumer Needs/Customer Preference Change
    8.3 Economic/Political Environmental Change

9 Global and Japan Live Attenuated Vaccine Market Size (Sales and Revenue) Forecast (2017-2022)
    9.1 Global and Japan Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    9.2 Global and Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
        9.2.1 by End User
        9.2.2 by Disease Indication
    9.3 Global and Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
    9.4 Global and Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)

10 Research Findings and Conclusion

11 Methodology and Data Source
    11.1 Methodology/Research Approach
        11.1.1 Research Programs/Design
        11.1.2 Market Size Estimation
        11.1.3 Market Breakdown and Data Triangulation
    11.2 Data Source
        11.2.1 Secondary Sources
        11.2.2 Primary Sources
    11.3 Disclaimer
    11.4 Author List


List of Tables and Figures

    Figure Product Picture of Live Attenuated Vaccine
    Table Japan Live Attenuated Vaccine Sales (Million Units) Comparison by Applications (2012-2017)
    Figure Japan Sales Market Share (%) of Live Attenuated Vaccine by Applications in 2016
    Table Global Live Attenuated Vaccine Sales (Million Units) Comparison by Applications (2012-2017)
    Figure Global Sales Market Share (%) of Live Attenuated Vaccine by Applications in 2016
    Figure Hospital Examples
    Table Key Downstream Customer in Hospital
    Figure Medical Center Examples
    Table Key Downstream Customer in Medical Center
    Figure Others Examples
    Table Key Downstream Customer in Others
    Figure Pediatrics Product Picture
    Figure Adults Product Picture
    Figure Pneumococcal Product Picture
    Figure Influenza Product Picture
    Figure HPV Product Picture
    Figure Hepatitis Product Picture
    Figure Rotavirus Product Picture
    Table Astellas Pharma (Japan) Basic Information List
    Table Astellas Pharma (Japan) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Astellas Pharma (Japan) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Astellas Pharma (Japan) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Astellas Pharma (Japan) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table CSL Limited (Australia) Basic Information List
    Table CSL Limited (Australia) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table CSL Limited (Australia) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table CSL Limited (Australia) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure CSL Limited (Australia) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Emergent BioSolutions (U.S.) Basic Information List
    Table Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Emergent BioSolutions (U.S.) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table GlaxoSmithKline (U.K.) Basic Information List
    Table GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure GlaxoSmithKline (U.K.) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Johnson & Johnson (U.S.) Basic Information List
    Table Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Johnson & Johnson (U.S.) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table MedImmune (U.S.) Basic Information List
    Table MedImmune (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table MedImmune (U.S.) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table MedImmune (U.S.) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure MedImmune (U.S.) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Merck & Co (U.S.) Basic Information List
    Table Merck & Co (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Merck & Co (U.S.) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Merck & Co (U.S.) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Merck & Co (U.S.) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Pfizer (U.S.) Basic Information List
    Table Pfizer (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Pfizer (U.S.) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Pfizer (U.S.) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Pfizer (U.S.) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Sanofi Pasteur (France) Basic Information List
    Table Sanofi Pasteur (France) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Sanofi Pasteur (France) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Sanofi Pasteur (France) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Sanofi Pasteur (France) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Serum Institute of India Pvt (India) Basic Information List
    Table Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales Growth Rate (%)(2012-2017)
    Table Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales Market Share (%) in Japan (2012-2017)
    Figure Serum Institute of India Pvt (India) Live Attenuated Vaccine Revenue Market Share (%) in Japan (2012-2017)
    Table Production Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of Live Attenuated Vaccine
    Figure Manufacturing Process Analysis of Live Attenuated Vaccine
    Figure Live Attenuated Vaccine Industrial Chain Analysis
    Table Raw Materials Sources of Live Attenuated Vaccine Major Players/Manufacturers in 2016
    Table Major Buyers of Live Attenuated Vaccine
    Table Distributors/Traders List
    Figure Japan Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
    Figure Japan Live Attenuated Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
    Figure Japan Live Attenuated Vaccine Price (USD/Pcs) Trend Forecast (2017-2022)
    Figure Global Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
    Figure Global Live Attenuated Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
    Figure Global Live Attenuated Vaccine Price (USD/Pcs) Trend Forecast (2017-2022)
    Table Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
    Table Global Live Attenuated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
    Figure Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
    Figure Global Live Attenuated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
    Figure Japan Live Attenuated Vaccine Sales Volume Market Share Forecast by Type in 2017
    Figure Global Live Attenuated Vaccine Sales Volume Market Share Forecast by Type in 2017
    Table Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
    Figure Japan Live Attenuated Vaccine Sales Volume Market Share Forecast by Application (2017-2022)
    Figure Japan Live Attenuated Vaccine Sales Volume Market Share Forecast by Application in 2017
    Table Global Live Attenuated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
    Figure Global Live Attenuated Vaccine Sales Volume Market Share Forecast by Application (2017-2022)
    Figure Global Live Attenuated Vaccine Sales Volume Market Share Forecast by Application in 2017
    Table Japan Live Attenuated Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)
    Table Japan Live Attenuated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
    Figure Japan Live Attenuated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
    Table Global Live Attenuated Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)
    Table Global Live Attenuated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
    Figure Global Live Attenuated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources

 



To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...
Choose License Type
Single User - US $3085
Multi User - US $6170
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify